C4 Therapeutics (CCCC) Insider Wilfred Buys 62,000 Shares
Ronald Cooper acquired 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Cooper Ronald Harold Wilfred bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- Ronald Cooper purchased 62,000 shares of C4 Therapeutics, Inc. (CCCC) on June 24, 2026.
- Shares of C4 Therapeutics traded near $4.26 on Saturday with a market cap of about $471 million.
- Analysts maintain a strong buy consensus with a mean price target of $13.33.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
On June 24, 2026, Ronald Cooper, an insider at C4 Therapeutics, Inc., bought 62,000 shares of the company. This transaction occurred without any pre-planned trading scheme and added to the insider activity in the biotech firm.
Insider Buying and Selling at C4 Therapeutics, Inc.
Several insiders at C4 Therapeutics, including Steven Hoerter, Utpal Koppikar, Laura Bessen, Stephen Fawell, and Owen Hughes, also purchased 62,000 shares each on the same day as Cooper. These transactions were not part of a Rule 10b5-1 plan.
C4 Therapeutics, Inc. Stock Up 25.7%
Shares of NasdaqGS:CCCC traded near $4.26 on Saturday. C4 Therapeutics, Inc. has a market cap of approximately $471 million and a forward P/E ratio that isn't meaningful because it isn't profitable. The stock has experienced a 52-week low of $1.40 and a high of $4.60. With a 50-day moving average of $3.51 and a 200-day moving average of $2.70, the company's beta stands at 2.93, indicating higher volatility compared to the broader market.
Analysts Set New Price Targets
Analyst firms have recently maintained their positive outlook on C4 Therapeutics. On June 1, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $12. Barclays has consistently kept a 'buy' rating, with a range of price targets, the latest being $7 on February 27, 2026. Overall, the consensus among analysts is a strong buy, with a mean target price of $13.33.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing therapies that degrade harmful proteins to treat diseases. The company’s lead candidate, Cemsidomide, targets multiple myeloma and has completed phase 1 trials. C4 Therapeutics is also working on other products for oncology and inflammation, with strategic partnerships with companies like Roche and Merck. Led by CEO Andrew J. Hirsch, the company employs 104 people.
Bottom Line
Insider buying at C4 Therapeutics highlights confidence in the company's future prospects. Investors watch these transactions closely as they can indicate management's belief in the company's potential. However, it's important to remember that insider activity is just one piece of the puzzle. Analyst ratings and market conditions also play significant roles in evaluating a stock's potential.
Related Filing Alerts
Source: Cooper Ronald Harold Wilfred's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts